U.S.-based AbbVie has reached a deal to acquire its European rival, Shire Pharmaceuticals, for about £32 billion ($58.6 billion).
Despite claims from critics, incremental innovations by drug companies provide great value for doctors and patients, according to a study.
The world of pharmaceuticals is changing. New, more effective medications are replacing older ones, more biologic treatments are being developed, advances are being made in treating catastrophic illnesses, and drug patents are expiring resulting in more and more generic alternatives becoming available. Canada’s population is changing, too. Our aging population means an increased demand for […]
Drug plan costs are an ongoing concern for Canadian employers. Benefits Canada’s Face to Face Drug Plan Management Forum in Vancouver shows how plan sponsors out west are managing them.
The Ordre des pharmaciens du Québec is looking at ways to ban drug loyalty cards in the province.
There is overwhelming evidence of the impact of wealth on people’s health, according to a report.
The money spent on pharmaceutical treatment in Ontario more than pays off in savings for the health system and improved productivity for the economy, according to a report.
Canada falls short of international standards when it comes to protecting intellectual property (IP) in the pharmaceutical industry, which could stifle trade and economic growth, according to a Fraser Institute report.
Canada's provincial pharmacare systems have flaws not found in other developed countries that could be addressed by integrating prescription drug coverage into the broader healthcare system, according to a report.
Canada has been looking at healthcare system the wrong way, according to the president of the Canadian Medical Association.